ES2989669T3 - Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana - Google Patents
Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Download PDFInfo
- Publication number
- ES2989669T3 ES2989669T3 ES20158066T ES20158066T ES2989669T3 ES 2989669 T3 ES2989669 T3 ES 2989669T3 ES 20158066 T ES20158066 T ES 20158066T ES 20158066 T ES20158066 T ES 20158066T ES 2989669 T3 ES2989669 T3 ES 2989669T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- hil
- binding
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title claims abstract description 125
- 102000055277 human IL2 Human genes 0.000 title claims abstract description 96
- 230000003308 immunostimulating effect Effects 0.000 title description 3
- 230000027455 binding Effects 0.000 claims abstract description 94
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 86
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 86
- 239000012634 fragment Substances 0.000 claims abstract description 51
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 102000036639 antigens Human genes 0.000 claims abstract description 48
- 108091007433 antigens Proteins 0.000 claims abstract description 48
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 21
- 230000005593 dissociations Effects 0.000 claims abstract description 21
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract description 19
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract description 19
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract description 19
- 241001529936 Murinae Species 0.000 claims abstract description 14
- 230000009260 cross reactivity Effects 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 238000000159 protein binding assay Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108700025316 aldesleukin Proteins 0.000 description 34
- 229940087463 proleukin Drugs 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 12
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 210000003289 regulatory T cell Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 108010032595 Antibody Binding Sites Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000000313 electron-beam-induced deposition Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- -1 Knotins Proteins 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 108010086186 avian pancreatic polypeptide Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- STGOXLCCKKFIGD-UHFFFAOYSA-N 1-hydroxy-2,5-dioxopyrrolidine-3,3-disulfonic acid Chemical class ON1C(=O)CC(S(O)(=O)=O)(S(O)(=O)=O)C1=O STGOXLCCKKFIGD-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108700004922 F42A Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 101001043830 Rattus norvegicus Interleukin-2 Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100024554 Tetranectin Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100021164 Vasodilator-stimulated phosphoprotein Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- YQMWQSMYVPLYDI-UHFFFAOYSA-N alpha-Isoaphyllin Natural products C12CCCCN2C(=O)C2C3CCCCN3CC1C2 YQMWQSMYVPLYDI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950001790 tendamistat Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- 108010013645 tetranectin Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176619 | 2014-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2989669T3 true ES2989669T3 (es) | 2024-11-27 |
Family
ID=51162588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20158066T Active ES2989669T3 (es) | 2014-07-10 | 2015-07-10 | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana |
| ES15759938T Active ES2779977T3 (es) | 2014-07-10 | 2015-07-10 | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15759938T Active ES2779977T3 (es) | 2014-07-10 | 2015-07-10 | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10894828B2 (OSRAM) |
| EP (2) | EP3166973B1 (OSRAM) |
| JP (1) | JP7209464B2 (OSRAM) |
| CN (1) | CN106604932B (OSRAM) |
| AU (1) | AU2015287227B2 (OSRAM) |
| CA (1) | CA2954476C (OSRAM) |
| DK (1) | DK3166973T3 (OSRAM) |
| ES (2) | ES2989669T3 (OSRAM) |
| WO (1) | WO2016005950A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43859A (fr) | 2016-01-11 | 2018-11-21 | Novartis Ag | Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion |
| MX2019003543A (es) | 2016-09-28 | 2019-06-17 | Xoma Us Llc | Anticuerpos que se fijan al interleucina-2 y sus usos. |
| GB201621806D0 (en) * | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| WO2018156955A1 (en) * | 2017-02-23 | 2018-08-30 | City Of Hope | Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd |
| JP7251792B2 (ja) | 2017-03-23 | 2023-04-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗Ｃ５ａ抗体とその使用 |
| JP7057980B2 (ja) * | 2017-05-25 | 2022-04-21 | インスティテュート フォー ベーシック サイエンス | 抗－ヒトインターロイキン－２抗体及びその用途 |
| US12454561B2 (en) | 2018-03-19 | 2025-10-28 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| JP2023509991A (ja) | 2020-01-13 | 2023-03-10 | シンアフィックス ビー．ブイ． | 抗体及び免疫細胞エンゲージャーのコンジュゲート |
| CN115397852B (zh) | 2020-02-16 | 2023-08-11 | 奥罗斯生物科学公司 | 工程化抗il-2抗体 |
| KR20230048151A (ko) * | 2020-08-18 | 2023-04-10 | 유니버시타트 취리히 | Cd25 편향된 항-il-2 항체 |
| CN117157107A (zh) | 2021-02-08 | 2023-12-01 | 西纳福克斯股份有限公司 | 多功能抗体 |
| CN118176217A (zh) | 2021-10-14 | 2024-06-11 | 徕特康(苏州)生物制药有限公司 | 新型抗体-细胞因子融合蛋白及其制备方法和用途 |
| US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
| CN119775409B (zh) * | 2025-03-05 | 2025-07-11 | 深圳真实生物医药科技有限公司 | 靶向sost的抗体及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA849910B (en) * | 1983-12-23 | 1985-09-25 | Hoffmann La Roche | Purification of recombinant interleukin-2 |
| JPS62269698A (ja) * | 1986-03-17 | 1987-11-24 | エフ．ホフマン ― ラ ロシュ アーゲー | Ｉｌ−２蛋白質に対するモノクロ−ナル抗体 |
| EP1947183B1 (en) | 1996-08-16 | 2013-07-17 | Merck Sharp & Dohme Corp. | Mammalian cell surface antigens; related reagents |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| WO2004060319A2 (en) | 2002-12-30 | 2004-07-22 | 3M Innovative Properties Company | Immunostimulatory combinations |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| AU2006254333B2 (en) | 2005-06-01 | 2011-02-17 | Amgen Research (Munich) Gmbh | Anti-IL2 antibodies |
| CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| CN101573139A (zh) * | 2006-02-16 | 2009-11-04 | 纳森特生物制剂公司 | 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法 |
| CN101045923B (zh) * | 2006-03-31 | 2011-11-23 | 沈阳三生制药有限责任公司 | 生产一种白细胞介素类似物的方法 |
| MX2010008786A (es) | 2008-02-11 | 2010-12-01 | Curetech Ltd | Anticuerpos monoclonales para tratamiento de tumores. |
| SG10201509330XA (en) | 2010-08-12 | 2015-12-30 | Lilly Co Eli | Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof |
| EP2673294B1 (en) | 2011-02-10 | 2016-04-27 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
-
2015
- 2015-07-10 ES ES20158066T patent/ES2989669T3/es active Active
- 2015-07-10 EP EP15759938.2A patent/EP3166973B1/en active Active
- 2015-07-10 AU AU2015287227A patent/AU2015287227B2/en not_active Ceased
- 2015-07-10 WO PCT/IB2015/055226 patent/WO2016005950A1/en not_active Ceased
- 2015-07-10 CA CA2954476A patent/CA2954476C/en active Active
- 2015-07-10 EP EP20158066.9A patent/EP3693389B1/en active Active
- 2015-07-10 CN CN201580048027.0A patent/CN106604932B/zh active Active
- 2015-07-10 ES ES15759938T patent/ES2779977T3/es active Active
- 2015-07-10 JP JP2017501280A patent/JP7209464B2/ja active Active
- 2015-07-10 US US15/324,468 patent/US10894828B2/en active Active
- 2015-07-10 DK DK15759938.2T patent/DK3166973T3/da active
-
2020
- 2020-12-22 US US17/131,221 patent/US20210230269A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2779977T3 (es) | 2020-08-21 |
| EP3693389C0 (en) | 2024-09-04 |
| CA2954476C (en) | 2023-09-19 |
| EP3693389A1 (en) | 2020-08-12 |
| AU2015287227B2 (en) | 2021-02-18 |
| CN106604932B (zh) | 2024-12-10 |
| EP3166973B1 (en) | 2020-02-19 |
| US10894828B2 (en) | 2021-01-19 |
| US20170183403A1 (en) | 2017-06-29 |
| DK3166973T3 (da) | 2020-04-06 |
| CA2954476A1 (en) | 2016-01-14 |
| AU2015287227A8 (en) | 2017-02-16 |
| EP3693389A9 (en) | 2021-04-07 |
| WO2016005950A1 (en) | 2016-01-14 |
| EP3693389B1 (en) | 2024-09-04 |
| AU2015287227A1 (en) | 2017-02-09 |
| JP7209464B2 (ja) | 2023-01-20 |
| JP2017525343A (ja) | 2017-09-07 |
| CN106604932A (zh) | 2017-04-26 |
| US20210230269A1 (en) | 2021-07-29 |
| EP3166973A1 (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2989669T3 (es) | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana | |
| JP7562528B2 (ja) | 抗体及びその用途 | |
| US10081680B2 (en) | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies | |
| ES2952132T3 (es) | Nuevo anticuerpo anti-pad4 | |
| US20170101473A1 (en) | Anti-wt1/hla-specific antibodies | |
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN117120477A (zh) | 针对密蛋白18a2和cd3的双特异性抗体及其应用 | |
| JP7711208B2 (ja) | Ｄｌｌ３に対する結合分子及びその使用 | |
| CN112094348A (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| KR102428255B1 (ko) | 위암의 검출 및 치료를 위한 조성물 및 방법 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| TWI882142B (zh) | 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途 | |
| CN115210263A (zh) | 抗axl抗体和组合物 | |
| ES2907717T3 (es) | Proteínas y usos | |
| CN120603848A (zh) | 三特异性抗原结合分子及其应用 | |
| CN115335402B (zh) | 特异性抗原结合分子,其制备方法及医药用途 | |
| WO2024017326A1 (zh) | 抗gprc5d纳米抗体及其应用 | |
| CN118215685A (zh) | 抗gucy2c抗体及其应用 | |
| RU2837590C1 (ru) | Антитела против axl и композиции | |
| RU2837590C9 (ru) | Антитела против axl и композиции | |
| WO2024012434A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| US20190194319A1 (en) | Anti-ascl1 antibodies and methods of use | |
| WO2018213680A1 (en) | Diagnostic antibodies and methods of use | |
| HK40049006B (en) | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof | |
| HK40049006A (en) | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof |